BridgeMD
New treatment option for Cognition Disorders in Old Age
Official title Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients
ClinicalTrials.gov ID: NCT07338682
What this study is testing
- What it's testing
- This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Age \>60 years
- Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
You likely can't join if
- Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
- Patients with history of L-arginine intolerance or allergy
- Patients with asthma
- Patients who recently had an acute myocardial infarction
- Patients with history of stroke within 1 yaear
- Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase...
See the full eligibility criteria
- Age \>60 years
- Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
- Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
- Patients with history of L-arginine intolerance or allergy
- Patients with asthma
- Patients who recently had an acute myocardial infarction
- Patients with history of stroke within 1 yaear
- Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.
- Patients who initiated or stopped antihypertensive medications during the study period.
- Patients who initiated or stopped antidiabetic medications during the study period.
- Patients who initiated or stopped antihyperlipidemic medications during the study period.
- Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function
- Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics
- Refusal to provide written informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.